Author:
van Diepen Sean,Mehta Rajendra H.,Leimberger Jeffrey D.,Goodman Shaun G.,Fremes Stephen,Jankowich Rachael,Heringlake Matthias,Anstrom Kevin J.,Levy Jerrold H.,Luber John,Nagpal A. Dave,Duncan Andra E.,Argenziano Michael,Toller Wolfgang,Teoh Kevin,Knight J. David,Lopes Renato D.,Cowper Patricia A.,Mark Daniel B.,Alexander John H.
Funder
Tenax pharmaceuticals
Duke Clinical Research Institute
Tenax Therapeutics
Bernard S. Goldman Chair in Cardiovascular Surgery
Fresenius Kabi
Bristol-Myers Squibb
GlaxoSmithKline
Medtronic
Pfizer
GE Healthcare
Lilly
Gilead Sciences
AstraZeneca
Bayer
Novartis
Eli Lilly and Company
Merck & Company
Oxygen Therapeutics
Boehringer Ingelheim
CryoLife
CSL Behring
Sanofi
VoluMetrix
Subject
Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery
Reference38 articles.
1. Coronary artery bypass grafting in patients with low ejection fraction;Topkara;Circulation,2005
2. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1—coronary artery bypass grafting surgery;Shahian;Ann Thorac Surg,2009
3. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass;Levin;Exp Clin Cardiol,2012
4. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome;Schumann;Cochrane Database Syst Rev,2018
5. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion;Toller;Int J Cardiol,2015
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献